How often should Trastuzumab be injected?

Trastuzumab (Trastuzumab) is an important and effective targeted anti-cancer drug. It has been used in the first-line treatment of HER2-overexpressing breast cancer, including adjuvant therapy and metastatic therapy. The frequency of trastuzumab injections depends on the specific treatment plan and condition. Typically, trastuzumab is administered intravenously once a week or every two weeks. When given as an intravenous infusion, trastuzumab is administered over 90 minutes weekly or every three weeks for breast cancer and every three weeks for gastric cancer.

For early-stage breast cancer, treatment is given for one year or until the disease returns, and for metastatic breast or stomach cancer, treatment is continued until it remains effective. Recommended dosage depends on the patient's weight and depends on the disease being treated and whether trastuzumab is given weekly or every three weeks. Infusions may cause allergic reactions, so patients should be monitored during and after the infusion, and patients who tolerate the first 90-minute infusion may receive subsequent infusions over 30 minutes. When injected subcutaneously, the recommended dose of trastuzumab does not depend on the patient's weight, with 600 mg administered over 2 to 5 minutes every three weeks.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.